Novartis AG Common Stock (NVS)

Novartis boasts a 26% net margin and a fortress balance sheet, while Teva's turnaround has returned it to profitability, but at what cost to stability?

Not every international ETF is a can't-miss investment opportunity.

VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.

When buying international dividend stocks, diversification is likely the best bet.

Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.

As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities.

Novartis acquires Myricx Bio for up to $1.5B to boost its oncology pipeline with a novel next-gen ADC cancer platform. Read more.

Compare portfolio concentration, risk profiles, and long-term growth as these two pharma ETFs take different approaches to capturing sector opportunity.

The best AI stocks might be in totally different industries, companies, and countries.

These international stock ETFs from iShares and Vanguard are very different once you look under the surface.

European stocks are outpacing the S&P 500 in 2026, and ArcelorMittal, Arm Holdings, and Novartis are three Euro Stoxx 50 components with index-beating returns.

These stocks are better bets to skyrocket than the much-hyped rocket stock.

Antares inks Novartis collaboration worth up to $1.9 billion to develop therapies targeting hard-to-treat cancers.

International stocks are trading for a steep discount, and here's a great way to invest.

Teva has been building its comeback, and the latest studies on Austedo and Austedo XR will help further that momentum.

Novartis reports positive Phase 1/2 del-brax data in FSHD, supporting Phase 3 development of a potential disease-modifying therapy.

When buying international ETFs, owning more stocks in more countries might be a better bet.

The Vanguard Total International Stock ETF's (VXUS) outperformance stems from where it invests.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer James Hamilton emphasizing that the company remains focused exclusively on siRNA therapeutics through

Yesterday's slow-growing economies might be tomorrow's best places to invest.

The most recent research report on the "Dry eye syndrome drugs Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic foreca

Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.

Expense ratios, asset size, and portfolio strategy set these two healthcare ETFs apart, yet their risk and dividend profiles tell a different story.

This little-discussed pipeline program could prove to be a big success.